Results from viability assays and measurements of BCL2 and caspase 3 in the H69V cell line suggest that KEAP1 silencing effectively affects the drug response, with contrasting effects on tumor cells when the two drugs were used separately. The gene discussed is BCL2; the disease is neoplasm.